Gå direkt till huvudinnehållet

Gastrointestinala komplikationer vid diabetes

Senast uppdaterad: Publicerad:
Sakkunnig:
  1. Shakil A, Church RJ, Rao SS. Gastrointestinal complications of diabetes. Am Fam Physician 2008; 77: 1697-1702. PubMed  
  2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86. New England Journal of Medicine  
  3. Bytzer P, Talley NJ, Leemon M, et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med 2001; 161: 1989-96. PubMed  
  4. Bytzer P, Talley NJ, Hammer J, Young LJ, Jones MP, Horowitz M. GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications. Am J Gastroenterol 2002; 97: 604-11. PubMed  
  5. Rayner CK, et al.Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001; 24: 371-81. PubMed  
  6. Ebert EC. Gastrointestinal complications of diabetes mellitus. Dis Mon 2005; 51: 620-63. PubMed  
  7. Lluch I, Ascaso JF, Mora F, et al. Gastroesophageal reflux in diabetes mellitus. Am J Gastroenterol 1999; 94: 919-24. PubMed  
  8. Camilleri M. Clinical practice. Diabetic gastroparesis. N Engl J Med 2007; 356: 820-9. New England Journal of Medicine  
  9. Yoshida MM, Schuffler MD, Sumi SM. There are no morphologic abnormalities of the gastric wall or abdominal vagus in patients with diabetic gastroparesis. Gastroenterology 1988; 94: 907-14. Gastroenterology  
  10. Ordög T, Takayama I, Cheung WK, Ward SM, Sanders KM. Remodeling of networks of interstitial cells of Cajal in a murine model of diabetic gastroparesis. Diabetes 2000; 49: 1731-9. PubMed  
  11. Parkman HP, Hasler WL, Fisher RS, et al. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004; 127: 1592-622. Gastroenterology  
  12. Tougas G, Chen Y, Coates G, et al. Standardization of a simplified scintigraphic methodology for the assessment of gastric emptying in a multicenter setting. Am J Gastroenterol 2000; 95: 78-86. PubMed  
  13. Jebbink RJ, Samsom M, Bruijs PP, et al. Hyperglycemia induces abnormalities of gastric myoelectrical activity in patients with type 1 diabetes mellitus. Gastroenterology 1994; 107: 1390-7. Gastroenterology  
  14. European Medicines Agency recommends changes to the use of metoclopramide www.ema.europa.eu  
  15. Galligan JJ, Vanner S. Basic and clinical pharmacology of new motility promoting agents. Neurogastroenterol Motil 2005; 17: 643-53. PubMed  
  16. Ramirez R, Stalcup P, Croft B, Darracq MA. Haloperidol undermining gastroparesis symptoms (HUGS) in the emergency department. Am J Emerg Med 2017. pmid:28320545 PubMed  
  17. Bujanda L. The effects of alcohol consumption upon the gastrointestinal tract. Am J Gastroenterol 2000; 95: 3374-82. PubMed  
  18. Anand C, Al-Juburi A, Familoni B, et al. Gastric electrical stimulation is safe and effective: a long-term study in patients with drug-refractory gastroparesis in three regional centers. Digestion 2007; 75: 83-9. PubMed  
  19. Jones MP, Maganti K. A systematic review of surgical therapy for gastroparesis. Am J Gastroenterol 2003; 98: 2122-9. PubMed  
  20. Maganti K, et al. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol 2003; 98: 259-63. PubMed  
  21. Virally-Monod M, Tielmans D, Kevorkian JP, et al. Chronic diarrhoea and diabetes mellitus: prevalence of small intestinal bacterial overgrowth. Diabetes Metab 1998; 24: 530-6. PubMed  
  22. Maleki D, et al. Pilot study of pathophysiology of constipation among community diabetics. Dig Dis Sci 1998; 43: 2373-8. PubMed  
  23. Angulo P, et al. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346:1221-31. New England Journal of Medicine  
  24. American Gastroenterological Association. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1702-4. Gastroenterology  
  25. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42: 132-8. PubMed  
  26. Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev, issue 1, 2007. The Cochrane Library  
  27. Basaranoglu M, et al. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999; 31: 384. PubMed  
  28. Zein CO, et al. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol 2005; 100: 48-55. PubMed  
  29. Petit JM, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001; 35: 279-83. PubMed  
  30. Fabris P, et al. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1998; 28: 514-7. PubMed  
  31. Vidal J, Ferrer JP, Esmatjes E, et al. Diabetes mellitus in patients with liver cirrhosis. Diabetes Res Clin Pract 1994; 25: 19-25. PubMed  
  32. Phelps G, Chapman I, Hall P, et al. Prevalence of genetic haemochromatosis in diabetic patients. Lancet 1989; 2: 233-4. PubMed  
  • Björn Eliasson, adjungerad professor och överläkare, Diabetescentrum, Sahlgrenska universitetssjukhuset, Göteborg

Tidigare sakkunniga

  • Terje Johannessen, professor i allmänmedicin, Institutt for samfunnsmedisinske fag, Norges teknisk-naturvitenskapelige universitet, Trondheim